QXL138AM
A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 100 patients (estimated)
- Sponsors
- Nammi Therapeutics Inc
- Tags
- CD138
- Trial Type
- Treatment
- Last Update
- 4 months ago
- SparkCures ID
- 1984
- NCT Identifier
- NCT06582017
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.